Journal
CARDIOLOGY IN REVIEW
Volume 17, Issue 1, Pages 44-47Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CRD.0b013e3181903b7f
Keywords
HIV; dyslipidemia; statins; antiretroviral therapy
Categories
Ask authors/readers for more resources
Patients living with the human immunodeficiency virus (HIV) are at risk for dyslipidemia as a result of the disease itself and from certain classes of antiretroviral therapy. The protease inhibitors and non-nucleoside reverse transcription inhibitors have been associated with elevated triglycerides, total, and low-density lipoprotein cholesterol with decreased high-density lipoprotein. These classes of medications affect the cytochrome P450 (CYP) enzyme resulting in both induction and inhibition of numerous CYP enzymes. The statins are extensively metabolized by the CYP system and therefore drug-drug interactions between the statins and antiretroviral therapy must be considered when treating HIV or antiretroviral drug-induced dyslipidemia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available